Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.

  1. Small Molecule Inhibitors of C. perfringens Epsilon-Toxin

    SBC: Innovative Biologics Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): C. perfringens epsilon-toxin (ETX) is a potential biological weapon included in the list of category B priority agents. The overall goal of this proposal is to identify and perform in vivo testing of new inhibitors of E TX using a novel approach for the inactivation of pore-forming toxins developed at Innovative Biologics, Inc. It is based on the blocking of th ...

    SBIR Phase II 2008 Department of Health and Human Services
  2. Multiplex Lyme Disease Diagnostic

    SBC: AGAVE BIOSYSTEMS INC.            Topic: N/A

    DESCRIPTION (provided by investigator): Lyme disease, caused by the gram-negative spirochete Borrelia burgdorferi and transmitted by Ixodid tick species, is the leading vector-borne infectious disease in the United States, with a steady rise in the number of cases reported each year. The most common Lyme disease symptom, the classic bull's-eye rash (erythema migrans or EM rash) in endemic areas, ...

    SBIR Phase I 2008 Department of Health and Human Services
  3. Lactoferrin Enhances Growth and Reduces Nosocomial Infection in Preterm Infants

    SBC: AGENNIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This project aims to develop talactoferrin (TLF, recombinant human lactoferrin) as a therapeutic agent to treat prematurely born neonates. The treatment will be given orally shortly after birth to prevent nosocomial inf ections (NIs) due to abnormal bacterial invasion of neonatal intestinal epithelia and consequently to limit systemic bacteremia and necrotizing ...

    SBIR Phase I 2008 Department of Health and Human Services
  4. Treatment of Sepsis with Talactoferrin

    SBC: AGENNIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Severe sepsis is a major cause of morbidity and mortality throughout the world. It is the leading cause of death in non-coronary intensive care units (ICUs) in the United States, with more than 750,000 cases occurring every year. This means that in the United States, more than 500 patients die from severe sepsis every day, with 28% to 50% of the patients succum ...

    SBIR Phase II 2008 Department of Health and Human Services
  5. New Reagents for Synthesizing Nuclease-resistant siRNA

    SBC: AM BIOTECHNOLOGIES, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The siRNA molecule needs better protection from nuclease degradation before it can be effectively used as a therapeutic. AM Biotechnologies (AM) will address this critical issue by developing ribonucleoside thiophospho ramidite (ABz, CBz, GIbu and U) reagents that will enable synthesis of phosphorodithioate siRNA (PS2-siRNA). This synthesized PS2-siRNA will si ...

    SBIR Phase I 2008 Department of Health and Human Services
  6. Novel RNA Markers for Detecting Colon Cancer Metastasis

    SBC: AMBION DIAGNOSTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Lymph node evaluation is an important prognostic factor in colorectal cancer (CRC) because accurate identification of lymph node metastases significantly influences survival. However, a 30% recurrence rate in patients w ith node-negative CRC clearly indicates that current staging methods are inadequate. The primary form of treatment for all stages of colon canc ...

    SBIR Phase I 2008 Department of Health and Human Services
  7. miRNA Profiling in Fixed Cancer Samples

    SBC: AMBION DIAGNOSTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): During Phase I of our proposed research, we will develop and validate procedures for recovering, labeling, and analyzing miRNAs from fixed tissue samples. The procedures will be based on the miRNA microarray and fix ed tissue RNA isolation systems that we developed in other SBIR-funded programs. The development of our miRNA isolation and labeling procedures ...

    SBIR Phase II 2008 Department of Health and Human Services
  8. MicroRNA biomarkers for early detection of prostate cancer

    SBC: AMBION DIAGNOSTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Prostate cancer (PrCa) is the most commonly diagnosed cancer in American men, with over 218,000 new cases diagnosed each year. It is second only to lung cancer in cancer mortality among men, and approximately 1 man in 5 will be diagnosed during his lifetime. When it is detected early, PrCa can be cured. In contrast, patients with metastatic prostate cancer hav ...

    SBIR Phase I 2008 Department of Health and Human Services
  9. RNA Amplification for Diagnostic Microarrays

    SBC: AMBION DIAGNOSTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this proposal is to develop and implement an integrated suite of technologies for enabling microarray-based diagnostic assays and the cGMP manufacturing processes and procedures necessary to manufact ure these products. Microarrays have found widespread use in biology and medicine as important tools for evaluating gene expression and genomic ...

    SBIR Phase I 2008 Department of Health and Human Services
  10. Streamlined labeling of degraded RNA for expression arrays

    SBC: AMBION DIAGNOSTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This is a proposal to develop a cGMP-manufactured RNA labeling kit suitable for clinical diagnostic assays and research applications that require multiplex RNA detection. The kit's target preparation technology will en able accurate and reproducible profiling of total RNA, including both microRNA (miRNA) and mRNA transcripts when combined with compatible micro ...

    SBIR Phase I 2008 Department of Health and Human Services
US Flag An Official Website of the United States Government